Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer
Treatment with the investigational next-generation KRAS-G12C inhibitor elisrasib led to clinical benefit in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12C mutation and whose disease progressed after prior therapies, according to resu
ORIGINAL SOURCE →via Medical Xpress
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · health
- [HEALTH] From crisis to commitment: nursing students' sense of belonging during and immediately after the covid-19 pandemic.
- [HEALTH] Knowledge, Attitudes, and Practices Regarding Arboviruses at a Human-Wildlife Interface: A Cross-Sectional Study in and
- [HEALTH] How to shore up trust during the "cold-period" between pandemics - closing the public trust gap in pandemic preparedness
- [HEALTH] Artificial intelligence at the frontlines: Emerging infectious and parasitic diseases in the digital era.
- [HEALTH] Emergency department evaluation and management of serious and high-risk infections in the febrile returning traveler.
- [HEALTH] Bluetongue Virus in Cervids in Piedmont During the 2024-2025 Outbreak.